A narrative review of the literature was conducted to determine if the administration of methylene blue (MB) in humans has potential risks. Studies were identified from MEDLINE, Web of Science, Scopus, and Cochrane. MB is a diagnostic substance used during some diagnostic procedures and also a part of the treatment of several diseases including methemoglobinemia, vasoplegic syndrome, fosfamide-induced encephalopathy, and cyanide intoxication, and the detection of leaks or position of parathyroid corpuscles during surgery. Although the use of MB is historically justified, and it ought to be safe, because it originated as a diagnostic material, the basic toxicological characteristics of this substance are unknown. Despite reports of severe adverse effects of MB, which could significantly exceed any possible benefits evaluated for the given indication. Therefore, the clinical use of MB currently represents a controversial problem given the heterogeneity of available data and the lack of preclinical data. This is in conflict with standards of safe use of such substances in human medicinal practice. The toxic effects of the application of MB are dose-dependent and include serious symptoms such as hemolysis, methemoglobinemia, nausea and vomitus, chest pain, dyspnoea, and hypertension. Some countries regard MB as harmful because of the resulting skin irritation and triggering of an adverse inflammatory response. MB induced serotoninergic toxicity clinically manifests as neuromuscular hyperactivity. This review aims to summarize the current understanding concerning the indications for MB administration and define the potential adverse effects of MB.

One of the most significant challenges of current medicine is the increasing prevalence of obesity worldwide that is accompanied by a wide range of chronic health complications and increased mortality. White adipose tissue actively contributes to metabolic regulation by production of a variety of hormones and cytokines, commonly referred to as adipokines. The spectrum and quantity of adipokines produced by the adipose tissue of obese patients is directly or indirectly involved in much obesity-related pathology (type 2 diabetes mellitus, cardiovascular disease, inflammatory response). One of the underlying mechanisms linking obesity, diabetes, and cardiovascular complications is subclinical inflammation, primarily arising in visceral adipose tissue. Adipocyte size, number and polarization of lymphocytes and infiltrated macrophages are closely related to metabolic and obesity-related diseases. The storage capacity of hypertrophic adipocytes in obese patients is limited. This results in chronic energy overload and leads to increased apoptosis of adipocytes that in turn stimulates the infiltration of visceral adipose tissue by immune cells, in particular macrophages. These cells produce many proinflammatory factors; while the overall production of anti-inflammatory cytokines and adipokines is decreased. The constant release of proinflammatory factors into the circulation then contributes to a subclinical systemic inflammation, which is directly linked to the metabolic and cardiovascular complications of obesity.

Background The aim of the study was to establish longitudinal bone changes in obese women after laparoscopic sleeve gastrectomy (LSG). Methods Twenty-nine women at baseline mean age of 40.41 ± 9.26 years and with mean body mass index (BMI) of 43.07 ± 4.99 kg/m² were included in a 6-month study. Skeletal status at hip [femoral neck (FN) and total hip (TH)] and spine was assessed at baseline, as well as in 3 and 6 months after surgery. Body size was measured at baseline and follow-up (weight, height, BMI, and waist). Results Baseline body weight was 117.5 ± 18.4 kg. The mean body weight and BMI decreased by 17.9 % during the first 3 months after surgery to obtain 28.4 % after 6 months. At 6 months, BMD decreased significantly for spine by 1.24 %, FN 6.99 %, and TH 5.18 %. The changes after 3 months in individual subjects showed that, in the majority of subjects, FN and TH BMD decreased significantly (in 52 % and 69 % of subjects, respectively), and in 24 % loss of BMD was found at the spine. After 6 months, the corresponding, significant decreases in individual subjects were found in 72 %, 86 %, and 38 % of woman, respectively. Those with a significant loss of FN BMD tended to lose more weight (30 ± 9.47 versus 23.25 ± 6.08 kg, p = 0.061) than others; women with a significant decrease of FN BMD lost more weight than those with no such decrease (30.43 ± 8.07 versus 15 ± 1.91 kg). Conclusion LSG proved efficient for body weight reduction, however, with a parallel decline in bone mineral density.

The prevalence of obesity continues to increase worldwide. Because obesity is associated with a number health-related problems as well as a shortened life span, treating obesity is an important clinical concern. Although various treatments are currently available, many are not efficacious in the long term. Therefore, additional medical treatment options for morbidly obese individuals must be explored. In this study, we examined the effects of the intragastric balloon MedSil® on anthropometric measures and hormones associated with lipid and energy metabolism.